3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
3
Breast Neoplasms
3
Smoldering Multiple Myeloma
1
Psoriasis
1
Polycystic Ovary Syndrome
1
Osteoarthritis
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Monoclonal Gammopathy of Undetermined Significance
1
Liver Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Autoimmune Diseases
1
Arthritis, Rheumatoid
1
Interventions
Cyclophosphamide
12
fludarabine phosphate
7
fludarabine
7
venetoclax
6
blinatumomab
6
Cytarabine
5
Lenalidomide
4
Dexamethasone
4
Blood Specimen Collection
4
Azacitidine
4
obinutuzumab
3
Rituximab
3
Radiotherapy
3
Melphalan
3
Immunotherapy, Adoptive
3
pembrolizumab
2
Neoadjuvant Therapy
2
Idarubicin
2
Chemotherapy, Adjuvant
2
Capecitabine
2
trastuzumab deruxtecan
1
tislelizumab
1
tisagenlecleucel
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
tagraxofusp
1
sacituzumab govitecan
1
sabatolimab
1
relugolix
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
Docosahexaenoic Acids
×
1 year
×
Clear all
No trials found.